1 **Nature and Trends of Pharmaceutical Payments to the Board Certified**
2 **Respiratory Specialists in Japan between 2016 and 2019**
3
4 **Short title: Pharmaceutical Payments to Japanese Respiratory Specialists**

5
6 **Authors:**

7 Anju Murayama^{1,2,*†}; Momoko Hoshi, RN^{1,3,†}; Hiroaki Saito, MD, PhD⁴; Sae
8 Kamamoto¹; Manato Tanaka¹; Moe Kawashima^{1,5}; Hanano Mamada¹; Eiji Kusumi, MD⁶;
9 Binaya Sapkota, BPharm, PharmD⁷; Sunil Shrestha, BPharm, PharmD⁸; Rajeev Shrestha,
10 BPharm⁹; Divya Bhandari, MSH; Toyoaki Sawano, MD, PhD¹⁰; Erika Yamashita¹;
11 Tetsuya Tanimoto, MD¹¹; Akihiko Ozaki, MD, PhD¹²

12
13 **Affiliations:**

14 ¹Medical Governance Research Institute, Minato-ku, Tokyo, Japan

15 ²Tohoku University School of Medicine, Sendai, Miyagi, Japan

16 ³Department of Public Health Nursing, Tohoku University Graduate School of
17 Medicine, Sendai, Miyagi, Japan

18 ⁴Department of Gastroenterology, Sendai Kosei Hospital, Sendai City, Miyagi,
19 Japan

20 ⁵Fukushima Medical University, Fukushima, Fukushima, Japan

21 ⁶Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku-ku, Tokyo,
22 Japan

23 ⁷Nobel College Faculty of Health Sciences, affiliated to Pokhara University, Kathmandu,
24 Nepal

25 ⁸School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar
26 Sunway, 47500, Jalan Lagoon Selatan, Malaysia

27 ⁹Department of Pharmacy, District Hospital Lamjung, Besisahar, Province
28 Gandaki, Nepal

29 ¹⁰Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki City,
30 Fukushima, Japan

31 ¹¹Department of Internal Medicine, Navitas Clinic, Tachikawa City, Tokyo, Japan

32 ¹²Department of Breast Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki

33 City, Fukushima, Japan

34

35 [†]Authors equally contributed to this study.

36 *Corresponding author

37

38 **Address correspondence to:** Anju Murayama, Medical Governance Research Institute,
39 2-12-13 Takanawa, Minato-ku, Tokyo, Japan, [ange21tera@gmail.com], 81-3-6455-
40 7401.

41

42 **Conflict of Interest Disclosures**

43 For financial conflicts of interest, Dr. Kusumi received personal fees from Otsuka
44 Pharmaceutical Co. Ltd outside the scope of the submitted work. Dr. Saito received
45 personal fees from TAIHO Pharmaceutical Co. Ltd outside the scope of the submitted
46 work. Drs. Ozaki and Tanimoto received personal fees from Medical Network Systems
47 outside the scope of the submitted work. Dr. Tanimoto also received personal fees from
48 Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial
49 conflicts of interest among the study authors, all are engaged in ongoing research
50 examining financial and non-financial conflicts of interest among healthcare
51 professionals and pharmaceutical companies in Japan. Individually, Anju Murayama,
52 Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, and Akihiko Ozaki contributed to
53 several published studies addressing conflicts of interest and quality of evidence among
54 clinical practice guideline authors in Japan and the United States. The other authors
55 have no example of conflicts of interest to disclose.

56

57 **Funding/Support**

58 This study was funded in part by the Medical Governance Research Institute. This non-
59 profit research organization received donations from a pharmaceutical company, Ain
60 Pharmacies, other organizations, and private individuals. This study also received
61 support from Tansa, an independent non-profit news organization dedicated to
62 investigative journalism. None of the entities providing financial support for this study
63 contributed to the design, execution, data analyses, interpretation of study findings, and
64 manuscript drafting.

65

66 **Keywords:**

67 Conflict of interest; Ethics; Health policy; Industry payment; Japan; Japanese

68 Respiratory Society; Physician payment; Respiratory Specialists

69

70 **Abstract**

71 **Background**

72 There are financial relationships between healthcare professionals and pharmaceutical
73 companies, and these relationships have historically caused conflicts of interest and
74 unduly influenced patient care. However, little was known about such relationship and
75 its effect in clinical practice among specialists in respiratory medicine.

77 **Methods**

78 Based on the retrospective analysis of payment data made available by all 92
79 pharmaceutical companies in Japan, this study evaluated the magnitude and trend of
80 financial relationships between all board-certified Japanese respiratory specialists and
81 pharmaceutical companies between 2016 and 2019. Magnitude and prevalence of
82 payments for specialists were analyzed descriptively. The payment trends were assessed
83 using the generalized estimating equations for the payment per specialist and the
84 prevalence of specialists with payments.

86 **Results**

87 Among all 7,114 respiratory specialists certified as of August, 2021, 4,413 (62.0%)
88 received a total of USD(\$) 53,547,391 and 74,195 cases from 72 (78.3%)
89 pharmaceutical companies between 2016 and 2019. The mean±SD and median
90 (interquartile range) four-year combined payment values per specialist were
91 \$12,134±\$34,045 and \$2,210 (\$715–\$8,178) respectively. At maximum, one specialist
92 received \$495,332 personal payments over the four years. Both payments per specialist
93 and prevalence of specialists with payments significantly increased during the four-year
94 period, with 7.8% (95% CI: 5.5–9.8; p<0.001) in payments and 1.5% (95% CI:
95 0.61%–2.4%; p = 0.001) in prevalence of specialists with payments, respectively.

96 **Conclusion**

97 Majority of respiratory specialists had increasingly received substantial personal
98 payments from pharmaceutical companies for the reimbursement of lecturing,
99 consulting, and writing between 2016 and 2019. These increasing financial relationships
100 with pharmaceutical companies might cause conflicts of interest among respiratory
101 physicians.

102

103 **Introduction**

104 Financial relationships between healthcare professionals and pharmaceutical companies
 105 might cause financial conflicts of interest (COIs) and jeopardize patient-centred care.
 106 Indeed, financial relationships between healthcare sectors and pharmaceutical
 107 companies might unintentionally influence physician prescribing patterns,¹⁻⁴
 108 recommendations of clinical guidelines,⁵⁻⁹ and conducting clinical research.¹⁰⁻¹⁴
 109 Therefore, proper management of COIs is currently one of the most fundamental
 110 challenges for all healthcare professionals.¹⁵ To increase transparency in financial COIs
 111 in healthcare, Japan Pharmaceutical Manufacturers Association (JPMA), the largest
 112 pharmaceutical trade organization in Japan, mandate all member companies to publish
 113 all payments made to the physicians, including those for lecturing, writing, and
 114 consulting, itemizing the value of payments along with individuals' names and
 115 affiliations on each company webpage from 2013 onwards, similar to the US Sunshine
 116 Act.¹⁶

117
 118 Among various specialties, respiratory medicine is one of the increasing markets for
 119 pharmaceutical companies alongside improvement in diagnostic technology and
 120 increase in patients with respiratory diseases such as asthma. The market size for
 121 respiratory medications is forecasted to increase from 38,985 million USD in 2019 to
 122 57,097 million USD in 2026 worldwide, and 2,519 million USD in 2019 to 3,160
 123 million USD in 2026 in Japan.¹⁷ Further, lung cancer is one of the most common cancer
 124 types in Japan, with 125,636 cases prevalent per year (12.8% of all cancer patients) in
 125 2018, ranking third out of 25 cancer types, and 75,394 annual deaths, ranking first out
 126 of 25 cancer types in 2019.¹⁸ The launch of mainly novel drugs for lung cancer
 127 contributed to the treatment of lung cancer and fierce market competition in Japan.¹⁷
 128 Consequently, the payments from pharmaceutical companies are expected to be
 129 increasingly concentrated on respiratory specialists in Japan, as did in other specialties
 130 such as hematology. However, no studies have assessed the magnitude or trends in
 131 payments from pharmaceutical companies to respiratory specialists in Japan.

132
 133 This study aimed to elucidate the prevalence of the board certified respiratory
 134 specialists receiving payment from pharmaceutical companies, the magnitude and trend
 135 of payments throughout recent years i.e., 2016-2019.

136

137 **Methods**

138 ***Participants***

139 This retrospective study considered all of the Japanese Respiratory Society (JRS)-
 140 certified respiratory specialists certified as of August 12, 2021. The JRS (hereafter
 141 named as the Society) was established in 1961, and is the primary and the largest
 142 medical professional society in respiratory medicine in Japan, with 12,976 Society
 143 members as of January 2021. The Society contributed to training, certifying the
 144 respiratory physicians or specialists in Japan, with a name list of the specialists publicly
 145 disclosed on the Society webpage, development of clinical practice guidelines for
 146 respiratory diseases, promoting research and continuing medical educations (CME) in
 147 respiratory medicine, and publishing several academic journals such as the *Respiratory*
 148 *Investigation* and *Respirology* in English, and the *Annals of the Japanese Respiratory*
 149 *Society* in Japanese.

150

151 ***Certification of respiratory specialists in Japan***

152 To become a respiratory specialist in Japan, physicians had to complete all of the
 153 following seven criteria: (1) should be board-certified in internal medicine by the
 154 Japanese Society of Internal Medicine (JSIM) or surgery by the Japan Surgical Society
 155 (JSS); (2) should complete specialized training in respiratory medicine for at least 3
 156 years at an institution accredited by the JRS after certification of an internal medicine
 157 specialist by the JSIM or a surgery specialist by the JSS; (3) must be a registered
 158 member of the JRS for at least three years; (4) must have three or more academic
 159 articles concerning respiratory medicine; (5) must attend clinical training course held by
 160 the JRS; (6) must be a non-smoker; and (7) must pass the written examination targeted
 161 for the respiratory specialist held by the JRS. Respiratory specialists need to renew their
 162 specialist certification every five years.

163

164 ***Data collection***

165 First, the name, affiliations, certification in teaching respiratory medicine, and address
 166 of all respiratory specialists were collected from the webpage of the JRS
 167 (<https://www.jrs.or.jp/modules/senmoni/>) on November 6, 2021. The payment data of
 168 JRS-certified respiratory specialists were extracted from all 92 pharmaceutical

169 companies affiliated to the JPMA and other associated companies from 2016 to 2019
 170 (19-21). The extracted data included recipients' names and affiliations, monetary
 171 amount (in USD), number of payment cases, payment category, and pharmaceutical
 172 companies' names. To remove payment data of different persons with similar names, we
 173 compared affiliations and recipients' special-ties between the data from the Society and
 174 the pharmaceutical companies. For payments to specialists whose affiliation and
 175 specialty reported by pharmaceutical companies differed from those reported by the JRS,
 176 we manually searched the name of respiratory specialists and collected additional data
 177 from official institutional web pages to verify whether they were the same persons,
 178 similar to previous studies^{19,20}

179
 180 According to the JPMA transparency guideline, only the payment concerning lecturing,
 181 writing, and consulting was disclosed along with individuals' names and affiliations and
 182 analysed based on individuals' specialists. Other types of personal payments such as
 183 meal, education, travel, and accommodations were not disclosed individually but only
 184 aggregated monetary value of these payments was disclosed by each company in
 185 Japan.¹⁶ Personal payments such as lecturing, writing, and consulting are directly and
 186 widely paid to physicians by pharmaceutical companies.^{3,21,22} Considering such nature
 187 of payments, the personal payments concerning lecturing, writing, and consulting were
 188 included in this study.

189 190 *Statistical Analysis*

191 Descriptive analyses of payment values and the number of cases were performed based
 192 on the specialists and the pharmaceutical companies. As a few companies such as Shire
 193 Japan and Baxalta did not disclose the number of payment cases, the payments from
 194 these companies were excluded from the analysis for payment cases. The Gini index
 195 and the shares of the payment values held by the top 1%, 5%, 10%, and 25% of
 196 specialists were used to examine the payment concentration. The Gini index measures
 197 income inequality among a given population, ranging from 0 to 1. The greater Gini
 198 index indicates a greater disparity in the distribution of payments on the specialist
 199 basis.²³⁻²⁶ Subgroup analyses were conducted to elucidate the geographical differences
 200 on prefecture and region level in the payments.

201

As the distribution of payments were highly right-skewed, the population-averaged generalized estimating equation (GEE) negative binomial regression model for the trend of payment value per specialist, and the linear GEE model log linked with binomial distribution for the trend of numbers of specialists with payments were used to evaluate payment trends through the four years. In addition, the relative percentage of the average annual increase in payments per specialist and in the prevalence of specialists with payments were used to report the results. The year of payments, and the proportion of physicians receiving payments and payment values were set as independent variable and dependent variable, respectively.²⁷⁻²⁹ Among data from 92 companies, 18 lacked payment data over the four years, because some companies were disaffiliated from the JPMA and others newly joined the JPMA. Therefore, we calculated only the payment trends of companies who had complete data of four-year. A two-sided $p < 0.05$ was considered statistically significant.

To adjust inflation and compare the payments across the study period, the Japanese yen (¥) was converted into the corresponding USD (\$) using the 2019 average monthly exchange rate of ¥109.0 per \$1. All analyses were conducted using Microsoft Excel, version 16.0 (Microsoft Corp), and Stata version 15 (StataCorp).

Ethical approval

The Ethics Committee of the Medical Governance Research Institute approved this study (approval number: MG2018-04-20200605; approval date: June 5, 2020). As this study was a retrospective analysis of publicly available information from pharmaceutical companies and the Society webpage, informed consent was waived by the Ethics Committee.

Results

A total of 7,114 respiratory specialists were certified by the JRS as of August 12, 2021, including 3,002 (42.2%) certified teaching respiratory specialists.

Overview of payments

Our payment database recorded 1,474,653 payment cases worth \$996,291,009 (¥108,595,720,027) from 92 pharmaceutical companies between 2016 and 2019. Of the

7,114 specialists, 4,413 (62.0%) received a total of \$53,547,391 (¥5,836,665,622) and 74,195 payment cases from 72 (78.3%: 72 out of 92) pharmaceutical companies over the same period (**Table 1**). The payment cases and values to the respiratory specialists occupied 5.0% and 5.4% of total cases and values, respectively. The mean±SD and median (interquartile range or IQR) four-year combined payment values per specialist were \$12,134±\$34,045 and \$2,210 (\$715–\$8,178), respectively. At maximum, one specialist received \$495,332 personal payments over the four years. The mean±SD and median (IQR) number of cases over the four years were 16.8±34.9 and 5.0 (2.0–16.0) cases per specialist. The respiratory specialists received the payments from 4.8±4.3; median: 3.0; and IQR: 1.0–7.0) pharmaceutical companies on average. Maximum 461 payment cases and 30 pharmaceutical companies per specialist were considered between 2016 and 2019.

While 38.0% of the specialists had no personal payments, 52.7%, 42.2%, 20.8%, 13.2%, 3.4%, and 1.6% of respiratory specialists received more than \$500, \$1,000, \$5,000, \$10,000, \$50,000 and \$100,000 in the four-year combined payments, respectively. The Gini index was 0.871 for the four-year combined total payments per specialist, indicating that only a small portion of the respiratory specialists received large amount of the personal payments. Top 1%, 5%, 10% and 25% of specialists occupied 30.3% (95% confidence interval (95% CI): 28.2%–32.4%), 64.8% (95% CI: 62.6%–67.0%), 79.3% (95% CI: 77.8%–80.8%), and 94.2% (95% CI: 93.7%–94.7%) of total monetary values, respectively. (Figure 1) The most common payment category was lecturing, occupying 85.6% of the total (\$45,847,076). The average and median payments for top 1% respiratory specialists were \$264,879±\$70,965 and \$247,747 (\$209,087–\$295,562), respectively. For payment cases per specialist, top 1% specialists received 241.4±67.8 cases in average, and 234 cases in median (195–288) during the four years, respectively.

Trends of payments

The average payments per specialist ranged \$4,270±\$10,590 in 2016 to \$5,081 ±\$11,520 in 2019, respectively. The average annual change rates marked significant increases in both payments per specialist by 7.6% (95% CI: 5.5%–9.8%; p <0.001) and prevalence of specialists with payments by 1.5% (95% CI: 0.61%–2.4%; p = 0.001).

268 Among 72 companies, there were six companies made payments to the specialists
269 without four-year payment data. Therefore, we limited payments from the remaining 66
270 companies with four-year data. Significant annual increases of payments and prevalence
271 of specialists with payments were also observed, with 7.8% (95% CI: 5.6–9.9;
272 $p < 0.001$) in payments and 1.6% (95% CI: 0.69%–2.5%; $p < 0.001$) in prevalence,
273 respectively.

274 ***Payments by company***

276 Among 72 pharmaceutical companies making payments to the specialists, payments
277 from the top 10 companies accounted for 74.4% of total payments with \$39,820,882
278 between 2016 and 2019. (Figure 2 and Supplemental Material 1) Particularly, the top
279 two companies with the largest amount, AstraZeneca and Boehringer Ingelheim Japan,
280 shared 19.8% (\$10,592,516) and 17.6% (\$9,428,840) of the total payments. The
281 payment types by top 10 paying companies are shown in Figure 3.

282 ***Geographical payment distribution***

284 There were significant geographical differences in the distribution of respiratory and
285 advising specialists in Japan (**Annex 2A and 2B**). The number of respiratory specialists
286 per million populations ranged from 28.6 in Aomori Prefecture to 86.0 in the Tokyo
287 Metropolis based on the prefecture. The total payment values per prefecture is shown in
288 **Annex 2C**. The average payment values per specialist were the highest in Miyagi
289 Prefecture (\$11,855) and the lowest in Oita Prefecture (\$3,707) (**Annex 2D**). For
290 analysis by region, the number of specialists per million populations ranged from 43.8
291 in Tohoku region (northernmost of Japan) to 64.7 in Kyusyu region (southernmost of
292 Japan), and adversely the average payments per specialist ranged from \$6,450 in
293 Kyusyu region to \$9,971 in Tohoku region.

294 **Discussion**

296 Based on the published evidence extracted from Medline/PubMed, Scopus, Web of
297 Science, and Google Scholar, this is the first study assessing the magnitude and trends of
298 the financial relationships between respiratory specialists and pharmaceutical
299 companies, which found that 5.4% of total personal payments from all pharmaceutical
300 companies were distributed to respiratory specialists, representing 2.2% (7,114 out of

301 327,210) of all physicians. Among 7,114 respiratory specialists in Japan, 4,413 (62.0%)
 302 accepted \$53,547,391 personal payments totaling 74,195 cases from 72 (78.3%)
 303 pharmaceutical companies between 2016 and 2019. Further, the respiratory specialists
 304 received \$12,134 personal payments with 16.8 times for the reimbursement of lecturing,
 305 consulting, and writing from 4.8 pharmaceutical companies on average in Japan. These
 306 financial interactions significantly increased by 7.8% in payment values per specialist
 307 and 1.6% in the prevalence of specialists receiving payments between 2016 and 2019.

308

309 First, we should note that there was dearth of research evaluating financial relationships
 310 between pharmaceutical companies and respiratory physicians worldwide. However,
 311 one study by Inoue et al.³⁰ assessed the financial relationships between physicians and
 312 pharmaceutical companies across 32 specialties in the US, and reported that
 313 pulmonology specialists received an average of \$2,689 in general payments such as
 314 lecturing, consulting, meals, travel, and accommodations between 2015 and 2017,
 315 namely \$896 per physician in one year. Comparing with their findings, we observed that
 316 the Japanese respiratory specialists received 4.8 to 5.7 times higher average annual
 317 payments of \$4,270 in 2016, and \$5,081 in 2019 (\$12,134 in four-year combined
 318 average). The discrepancy could have been resulted due to differences in payment
 319 categories and a different definition of respiratory specialists between their study in the
 320 US and our study in Japan. Nevertheless, our findings indicated strong financial
 321 relationships between respiratory physicians and pharmaceutical companies in Japan.

322

323 Meanwhile, other studies outside of respiratory specialists reported that there were
 324 lower average payments among the US nephrology specialists (\$1,795–\$2,227 annual
 325 general payments)³¹, the US orthopedic surgery (\$3,260 in 2013), and the US
 326 dermatologists (\$4,177)²² than the Japanese respiratory specialists; while several
 327 specialists such as the US ophthalmologists (\$5,191)³²; the US cardiologists (\$5,638)³³;
 328 the US rheumatologists (\$6,444)³⁴; and Japanese respiratory oncologists (\$6,992)¹⁹
 329 received higher average payments. Particularly, this study represented large financial
 330 relationships of JRS-certified specialists with pharmaceutical companies as compared to
 331 other specialists in the US and Japan.

332

333 One of the primary findings of this study was that both the magnitude and prevalence of

334 payments for respiratory specialists in Japan increased significantly during the past four
335 years, with a 7.8% average annual increase in payments per specialist, and 1.6% in the
336 prevalence of specialists with payments. This finding was consistent with previous
337 studies conducted among US oncologists²⁸ and Japanese hematologists. Although
338 Marshall et al. reported that overall payment values and the number of physicians
339 receiving payments declined since the introduction of the US Open Payment
340 Database,²⁹ greater payments were increasingly concentrated on a smaller proportion of
341 the US oncologists.²⁸ Furthermore, Kusumi et al. reported that both payments and
342 prevalence of hematologists with payments constantly increased with a significant
343 average annual increase of 10.4% and 2.9%, respectively. As Ozaki et al. previously
344 reported, the Japanese respiratory oncologists received the highest personal payments in
345 2016 due to the launch of the multiple novel oncology drugs for non-small cell lung
346 cancer (NSCLC).¹⁹

347 Among the top 10 largest paying companies, in particular, the total annual payments
348 from AstraZeneca, the largest paying company, constantly increased from \$1,842,153 in
349 2016 to \$3,403,281 in 2019. Meanwhile, Boehringer Ingelheim, the second largest
350 paying company, remained stable, ranging from \$2,317,265 in 2016 to \$2,412,839 in
351 2017. This increasing trend would also be due to the invent of several novel drugs for
352 lung cancers. For example, osimertinib (TAGRISSO® from AstraZeneca) was approved
353 for stage III NSCLC in March 2016, and then it was strongly recommended as a first-
354 line treatment for stage III NSCLC in Japan since 2018.³⁵ Consequently, \$751 million
355 worth osimertinib was sold in 2019, accounting for the largest share of all oral
356 molecular targeted drugs in Japan.³⁶ Also, durvalumab (IMFINZI® from AstraZeneca)
357 received its first approval as an immune checkpoint inhibitor for NSCLC in Japan in
358 July 2018.³⁵

359

360 Aside from lung cancer drugs, there have been remarkable changes in asthma and
361 chronic obstructive pulmonary disease (COPD) treatment. Although previously
362 monotherapy with inhaled corticosteroids (ICS) was the first-line treatment for COPD,
363 current clinical guidelines such as the Global Initiative for Chronic Obstructive Lung
364 Disease (GOLD) guideline and the JRS guideline recommended dual therapy with the
365 long-acting muscarinic antagonist (LAMA) and long-acting β 2-agonist (LABA) or ICS
366 and LABA over monotherapy of ICS or LABA.^{37,38} Following to these changes in

367 guideline recommendations, several companies such as Boehringer Ingelheim,
368 AstraZeneca, and GlaxoSmithKline developed combination drugs of LAMA/LABA,
369 ICS/LABA, and further ICS/LAMA/LABA.³⁶ Furthermore, novel biological drugs for
370 asthma treatment have been increasingly developed, such as omalizumab (XOLAIR®
371 from Novartis Pharma, approved for asthma in 2009); mepolizumab (NUCALA® from
372 GlaxoSmithKline, approved asthma and COPD in 2016); benralizumab (FASENRA®
373 from AstraZeneca, approved for asthma in 2018); and dupilumab (DUPIXENT® from
374 Sanofi, approved for asthma in 2019).³⁶ Considering the recent development of novel
375 drugs in respiratory medicine, the personal payments from pharmaceutical companies to
376 respiratory specialists are expected to increase in Japan in the future.

377

378 **Limitations**

379 First, as previously noted, the payment database was structured by the manual collection
380 of payment data from 92 pharmaceutical companies and cross-checked to exclude
381 duplicate physicians from the data. Therefore, this study might have included a few
382 unavoidable human errors, but our repeated and careful scrutiny of payment data by
383 more than two independent reviewers could have minimized such errors. Second,
384 currently, pharmaceutical companies do not disclose their payments concerning meals,
385 beverages, accommodations, travel, and stock ownerships. This might have led to
386 underestimations of the extent and prevalence of overall financial relationships between
387 respiratory specialists and industries. However, such information was not available and
388 the JPMAdoes not mandate to disclose such information on an individual basis.

389

390 **Conclusion**

391 The majority of respiratory specialists board certified by the Japanese Respiratory
392 Society increasingly received personal payments for the reimbursements of lecturing,
393 consulting, and writing from the pharmaceutical companies. These financial
394 relationships with pharmaceutical companies were potential COI, and the vast majority
395 of these payments concentrated on only a tiny proportion of specialists. Therefore, we
396 believed this study would reach all respiratory medicine stakeholders, including patients,
397 healthcare professionals, and policymakers, and promote discussion for better
398 healthcare with harmony between patients, healthcare professionals, and industries.

399

400 Acknowledgement

401 The authors thank the Tansa (formerly known as Waseda Chronicle) for providing
402 payment data. Also, we appreciate Mr. Souto Nagano, an undergraduate student from
403 the Faculty of Letters, University of Tokyo; Mr. Kohki Yamada, a medical student at the
404 Osaka University School of Medicine; Mr. Takuto Sakaemura, an undergraduate student
405 from faculty of Applied Science; and Ms. Megumi Aizawa, a graduate student from the
406 Department of Industrial Engineering and Economics, School of Engineering, Tokyo
407 Institute of Technology, for their dedicated contribution on collecting and cross-
408 checking the payment data.

409

410

411 References

- 412 1. DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA.
413 Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns
414 for Medicare Beneficiaries. *JAMA Internal Medicine*. 2016;176(8):1114-1122.
- 415 2. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are Financial Payments From the
416 Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic
417 Review. *Ann Intern Med*. 2020.
- 418 3. Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN.
419 Industry Payments to Physician Specialists Who Prescribe Repository
420 Corticotropin. *JAMA Network Open*. 2018;1(2):e180482-e180482.
- 421 4. Modi PK, Wang Y, Kirk PS, Dupree JM, Singer EA, Chang SL. The Receipt of
422 Industry Payments is Associated With Prescribing Promoted Alpha-blockers and
423 Overactive Bladder Medications. *Urology*. 2018;117:50-56.
- 424 5. Nejstgaard CH, Bero L, Hrobjartsson A, et al. Association between conflicts of
425 interest and favourable recommendations in clinical guidelines, advisory
426 committee reports, opinion pieces, and narrative reviews: systematic review.
427 *BMJ*. 2020;371:m4234.
- 428 6. Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Are Clinical Practice
429 Guideline for Hepatitis C by the American Association for the Study of Liver
430 Disease and Infectious Diseases Society of America Evidence-based? Financial
431 Conflicts of Interest and Assessment of Quality of Evidence and Strength of
432 Recommendations. *Hepatology*. 2021;n/a(n/a).

- 433 7. Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of
434 America to redo Lyme guidelines due to flawed development process. *J Med*
435 *Ethics*. 2009;35(5):283-288.
- 436 8. Coyne DW. Influence of Industry on Renal Guideline Development. *Clinical*
437 *Journal of the American Society of Nephrology*. 2007;2(1):3-7.
- 438 9. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A.
439 Evaluation of Financial Conflicts of Interest and Drug Statements in the
440 Coronavirus Disease 2019 Clinical Practice Guideline in Japan. *Clin Microbiol*
441 *Infect*. 2021.
- 442 10. Tijdink JK, Smulders YM, Bouter LM, Vinkers CH. The effects of industry
443 funding and positive outcomes in the interpretation of clinical trial results: a
444 randomized trial among Dutch psychiatrists. *BMC Med Ethics*. 2019;20(1):64.
- 445 11. Ozaki A. Conflict of Interest and the CREATE-X Trial in the New England
446 Journal of Medicine. *Sci Eng Ethics*. 2018;24(6):1809-1811.
- 447 12. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and
448 research outcome. *Cochrane Database Syst Rev*. 2017;2(2):MR000033.
- 449 13. Wilson JM. Lessons learned from the gene therapy trial for ornithine
450 transcarbamylase deficiency. *Mol Genet Metab*. 2009;96(4):151-157.
- 451 14. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T. Payments From
452 Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in
453 Japan. *JAMA Netw Open*. 2019;2(5):e193817.
- 454 15. Medicine AFABoI, Medicine A-AFACoP-ASoI, European Federation of Internal
455 M. Medical professionalism in the new millennium: a physician charter. *Ann*
456 *Intern Med*. 2002;136(3):243-246.
- 457 16. Ozaki A, Saito H, Senoo Y, et al. Overview and transparency of non-research
458 payments to healthcare organizations and healthcare professionals from
459 pharmaceutical companies in Japan: Analysis of payment data in 2016. *Health*
460 *Policy*. 2020;124(7):727-735.
- 461 17. QYResearch. *Global and Japan Respiratory Drug Market Insights, Forecast to*
462 *2026*. QYResearch 2020.
- 463 18. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T. Population-
464 based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a
465 chronological and international comparative study. *Jpn J Clin Oncol*.

- 2011;41(1):40-51.
19. Ozaki A, Saito H, Onoue Y, et al. Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis. *BMJ Open*. 2019;9(9):e028805.
20. Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan. *JAMA Netw Open*. 2019;2(4):e192834.
21. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. *JAMA*. 2017;317(17):1774-1784.
22. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data. *JAMA Dermatol*. 2016;152(12):1307-1313.
23. Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. *PLoS One*. 2020;15(10):e0239610.
24. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. *Int Urogynecol J*. 2021;32(2):443-451.
25. Ozieranski P, Csanadi M, Rickard E, Tchilingirian J, Mulinari S. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015. *JAMA Netw Open*. 2019;2(6):e196253.
26. Nalleballe K, Sheng S, Li C, et al. Industry Payment to Vascular Neurologists: A 6-Year Analysis of the Open Payments Program From 2013 Through 2018. *Stroke*. 2020;51(4):1339-1343.
27. Marshall DC, Tarras ES, Rosenzweig K, et al. Trends in Financial Relationships Between Industry and Radiation Oncologists Versus Other Physicians in the United States from 2014 to 2018. *International Journal of Radiation Oncology*Biophysics*. 2021;109(1):15-25.
28. Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry Payments to Medical Oncologists in the United States Since the

499 Inception of the Open Payments Program, 2014 to 2019. *JAMA Oncology*.
500 2021;7(3):440-444.

501 29. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in
502 Industry Payments to Physicians in the United States From 2014 to 2018. *JAMA*.
503 2020;324(17):1785-1788.

504 30. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between
505 physician characteristics and payments from industry in 2015-2017:
506 observational study. *BMJ Open*. 2019;9(9):e031010.

507 31. Pakanati AR, Kovvuru K, Thombre V, Kanduri SR, Nalleballe K, Ranabothu S.
508 Industry Payments to Nephrologists in the United States. *Cureus*.
509 2021;13(8):e17057.

510 32. Slentz DH, Nelson CC, Lichter PR. Characteristics of Industry Payments to
511 Ophthalmologists in the Open Payments Database. *JAMA Ophthalmology*.
512 2019;137(9):1038-1044.

513 33. Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP.
514 Industry Payments to Cardiologists. *Circulation: Cardiovascular Quality and*
515 *Outcomes*. 2018;11(12):e005016.

516 34. Putman MS, Goldsher JE, Crowson CS, Duarte-García A. Industry Payments to
517 Practicing US Rheumatologists, 2014–2019. *Arthritis & Rheumatology*.
518 2021;73(11):2138-2144.

519 35. The Japan Lung Cancer Society. The 2021 Edition of the Clinical Guidelines for
520 Lung Cancer. 2021;
521 https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3. Accessed
522 January 16, 2022.

523 36. Jiho. *Yakuji Handbook 2021*. Jiho; 2021.

524 37. Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the*
525 *diagnosis, management, and prevention of chronic obstructive pulmonary*
526 *disease: GOLD 2022 report*. Online2022.

527 38. Japanese Respiratory Society. *The JRS Guidelines for the Management of*
528 *Chronic Obstructive Pulmonary Disease*. 5th edition ed: Japanese Respiratory
529 Society; 2018.

530

Table 1. Summary of personal payments from pharmaceutical companies to respiratory specialists certified by the Japanese Respiratory Society between 2016 and 2019

Variables	
Total payments, \$	
Payment values, \$	53,547,391
Cases, n	74,195
Companies, n	72
Average per specialist±SD	
Payment values, \$	12,134±34,045
Cases, n	16.8±34.9
Companies, n	4.8±4.3
Median (IQR)	
Payment values, \$	2,210 (715□8,178)
Cases, n	5.0 (2.0□16.0)
Companies, n	3.0 (1.0□7.0)
Range	
Payment values, \$	31□495,332
Cases, n	1.0□461
Companies, n	1.0□30
Physicians with specific payments, n (%)	
Any payments	4,413 (62.0)
Payments >\$500	3,747 (52.7)
Payments >\$1,000	3,000 (42.2)
Payments >\$5,000	1478 (20.8)
Payments >\$10,000	940 (13.2)
Payments >\$50,000	239 (3.4)
Payments >\$100,000	111 (1.6)
Gini index	0.871
Category of payments, \$ (%)	
Lecturing	45,847,076 (85.6)
Consulting	5,770,483 (10.8)
Writing	1,701,141 (3.2)
Other	228,691 (0.43)

IQR: interquartile range; SD: standard deviation

Table 2. Trend of personal payments from pharmaceutical companies to respiratory specialists certified by the Japanese Respiratory Society between 2016 and 2019

Variables	2016	2017	2018	2019	Average yearly change (95%CI), %	P-value	Combined total
All pharmaceutical companies							
Total payments , \$ (¥)	12,439,754 (1,355,933,145)	12,025,229 (1,310,749,925)	13,911,371 (1,516,339,453)	15,171,038 (1,653,643,099)	□	□	53,547,391 (5,836,665,622)
Average payments±SD, \$	4,270±10,590	4,368±10,531	4,689±10,492	5,081±11,520	7.6 (5.5□9.8)	<0.001	12,134±34,045
Median payments (IQR), \$	1,085 (511□3,192)	1,124 (511□3,325)	1,328 (511□3,795)	1,428 (520□4,034)			2,210 (715□8,178)
Payment range, \$	85□138,421	51□129,078	92□149,569	31□117,871	□	□	31□495,332
Physicians with specific payments, n (%)							
Any payments	2,913 (40.9)	2,753 (38.7)	2,967 (41.7)	2,986 (42.0)	1.5 (0.61□2.4)	0.001	4,413 (62.0)
Payments >\$500	2,261 (31.8)	2,174 (30.6)	2,398 (33.7)	2,457 (34.5)	3.6 (2.5□4.6)	<0.001	3,747 (52.7)
Payments >\$1,000	1,568 (22.0)	1,490 (20.9)	1,724 (24.2)	1,806 (25.4)	6.0 (4.7□7.3)	<0.001	3,000 (42.2)
Payments >\$5,000	508 (7.1)	504 (7.1)	593 (8.3)	634 (8.9)	8.7 (6.3□11.2)	<0.001	1478 (20.8)
Payments >\$10,000	261 (3.7)	269 (3.8)	311 (4.4)	331 (4.7)	9.0 (5.7□12.4)	<0.001	940 (13.2)
Payments >\$50,000	38 (0.53)	34 (0.48)	40 (0.56)	49 (0.69)	10.2 (-0.76□22.4)	0.069	239 (3.4)
Payments >\$100,000	6 (0.084)	5 (0.070)	2 (0.028)	6 (0.084)	-6.1 (-32.5□30.5)	0.71	111 (1.6)
Gini index	0.892	0.897	0.884	0.885	□	□	0.871
Pharmaceutical companies with 4-years payment data^a							
Total payments , \$	12,329,176 (1,343,880,199)	12,010,489 (1,309,143,306)	13,846,437 (1,509,261,613)	15,102,239 (1,645,960,030)	□	□	53,286,653 (5,808,245,148)
Average payments±SD, \$	4,259±10,517	4,367±10,519	4,679±10,470	5,073±11,490	7.8 (5.6□9.9)	<0.001	12,113±33,943
Median payments (IQR), \$	1,093 (511□3,180)	1,124 (511□3,326)	1,328 (511□3,780)	1,420 (520□4,005)			2,214 (715□8,169)
Payment range, \$	85□136,230	51□129,078	92□149,569	31□117,871	□	□	31□495,332
Physicians with specific payments, n (%)							
Any payments	2895 (40.7)	2750 (38.7)	2959 (41.6)	2977 (41.8)	1.6 (0.69□2.5)	0.001	4,399 (61.8)
Payments >\$500	2248 (31.6)	2171 (30.5)	2391 (33.6)	2452 (34.5)	3.7 (2.6□4.7)	<0.001	3,734 (52.5)
Payments >\$1,000	1562 (22.0)	1489 (20.9)	1714 (24.1)	1803 (25.3)	6.0 (4.7□7.3)	<0.001	2,991 (42.0)
Payments >\$5,000	503 (7.1)	504 (7.1)	591 (8.3)	632 (8.9)	8.9 (6.4□11.4)	<0.001	1,472 (20.7)
Payments >\$10,000	259 (3.6)	268 (3.8)	310 (4.4)	330 (4.6)	9.2 (5.9□12.5)	<0.001	931 (13.1)
Payments >\$50,000	37 (0.52)	33 (0.46)	40 (0.56)	48 (0.67)	10.7 (-0.36□23.0)	0.058	239 (3.4)
Payments >\$100,000	6 (0.084)	5 (0.070)	2 (0.028)	6 (0.084)	-6.1 (-32.5□30.5)	0.71	110 (1.6)
Gini index	0.892	0.897	0.884	0.885	□	□	0.871

IQR: interquartile range; **SD:** standard deviation

Figure 1. Pharmaceutical payment concentration among the respiratory specialists in Japan

Figure 2. Total payments to respiratory specialists made by the top 10 largest paying companies between 2016 and 2019

Figure 3. Payment category by the pharmaceutical companies

Annex 1. Value of personal payments by top ten pharmaceutical companies from 2016 to 2019

Company name	Year, \$				Combined total, US% (%)
	2016	2017	2018	2019	
AstraZeneca	1,842,153	2,276,273	3,070,809	3,403,281	10,592,516 (19.8)
Boehringer Ingelheim Japan	2,317,265	2,412,839	2,354,322	2,344,415	9,428,840 (17.6)
Chugai Pharmaceutical	733,807	754,831	1,149,723	1,266,167	3,904,528 (7.3)
Merck Sharp & Dohme	579,941	769,027	831,594	722,307	2,902,870 (5.4)
Ono Pharmaceutical	805,806	660,644	671,655	374,515	2,512,620 (4.7)
Novartis Pharma	440,855	351,253	608,614	1,098,319	2,499,041 (4.7)
Kyorin Pharmaceutical	752,102	495,036	601,077	584,490	2,432,705 (4.5)
Pfizer Japan	569,670	545,174	432,017	355,677	1,902,539 (3.6)
Taiho Pharmaceutical	399,571	488,742	521,074	457,771	1,867,159 (3.5)
Bristol Myers Squibb	389,440	496,347	542,435	349,841	1,778,064 (3.3)

Annex 2A: Geographical differences in number of respiratory specialists per million population in 2021; 2B: number of teaching respiratory specialists per million population in 2021; 2C: total personal payment values from 2016 to 2019; 2D: average personal

payment values per respiratory specialist from 2016 to 2019